John Nuss Sells 13,161 Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) Stock

Ventyx Biosciences, Inc. (NASDAQ:VTYX) insider John Nuss sold 13,161 shares of the stock in a transaction on Thursday, December 19th. The stock was sold at an average price of $2.26, for a total transaction of $29,743.86. Following the transaction, the insider now directly owns 485,701 shares in the company, valued at $1,097,684.26. The trade was a 2.64 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Ventyx Biosciences Price Performance

VTYX stock opened at $2.24 on Friday. The stock has a market capitalization of $158.39 million, a price-to-earnings ratio of -0.95 and a beta of 0.48. The company has a 50-day moving average of $2.30 and a two-hundred day moving average of $2.38. Ventyx Biosciences, Inc. has a 52-week low of $1.67 and a 52-week high of $11.48.

Institutional Trading of Ventyx Biosciences

Hedge funds have recently added to or reduced their stakes in the business. Acadian Asset Management LLC acquired a new position in shares of Ventyx Biosciences during the second quarter worth approximately $608,000. Vestal Point Capital LP increased its position in Ventyx Biosciences by 31.2% during the third quarter. Vestal Point Capital LP now owns 1,725,000 shares of the company’s stock worth $3,760,000 after acquiring an additional 410,000 shares during the period. Deerfield Management Company L.P. Series C raised its stake in Ventyx Biosciences by 64.6% during the 2nd quarter. Deerfield Management Company L.P. Series C now owns 5,829,570 shares of the company’s stock valued at $13,466,000 after purchasing an additional 2,287,570 shares during the last quarter. Sio Capital Management LLC boosted its holdings in Ventyx Biosciences by 153.2% in the 3rd quarter. Sio Capital Management LLC now owns 1,971,948 shares of the company’s stock valued at $4,299,000 after purchasing an additional 1,193,024 shares during the period. Finally, Cubist Systematic Strategies LLC grew its position in Ventyx Biosciences by 165.8% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 149,500 shares of the company’s stock worth $345,000 after purchasing an additional 93,247 shares during the last quarter. Institutional investors own 97.88% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on VTYX. HC Wainwright reiterated a “neutral” rating and set a $6.00 price target on shares of Ventyx Biosciences in a research note on Monday, November 11th. Oppenheimer reaffirmed an “outperform” rating and set a $9.00 target price (down previously from $10.00) on shares of Ventyx Biosciences in a research report on Friday, November 8th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, Ventyx Biosciences presently has an average rating of “Moderate Buy” and a consensus price target of $10.00.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.